Table 2.
Uses of EAE
| General | Neuroprotective strategies |
| Immunosuppressive drugs | |
| Neurotransmitters in inflammation | |
| Channel function during inflammation, demyelination and remyelination | |
| Immune responses in immunologically privileged sites | |
| Effects of cytokines in the CNS | |
| Blood–brain barrier function and dysfunction | |
| Immunological tolerance | |
| T-cell receptor restriction | |
| Epitope spreading | |
| Regulatory T cells | |
| Specific to CNS inflammation, demyelination | Development, testing and validation of MS drugs: bioavailability, pharmacokinetics, preclinical efficacy, safety |
| Development and testing of drugs with possible dual action on the CNS and immune system, for development of drugs with both immunomodulatory and neuroprotective properties | |
| Gene expression during demyelination a remyelination | |
| Gene expression profiling for discovery and validation of new targets for MS treatment | |
| Expression of genes associated with sparing of CNS elements or resolution of inflammation | |
| Mechanisms of axonal damage and loss | |
| Study of symptoms and symptomatic treatment for MS: e.g. spasticity and anti-spastic drugs, bladder dysfunction, pain |